Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.

导出 OA

翻译打印收藏纠错

作者： Samit K,Bhattacharya ^[1] ; Kim,Andrews ^[1] ; Ramsay,Beveridge ^[1] ; Kimberly O,Cameron ^[1] ; Chiliu,Chen ^[1] ; Matthew,Dunn ^[1] ; Dilinie,Fernando ^[1] ; Hua,Gao ^[1] ; David,Hepworth ^[1] ; V Margaret,Jackson ^[1] ; Vishal,Khot ^[1] ; Jimmy,Kong ^[1] ; Rachel E,Kosa ^[1] ; Kimberly,Lapham ^[1] ; Paula M,Loria ^[1] ; Allyn T,Londregan ^[1] ; Kim F,McClure ^[1] ; Suvi T M,Orr ^[1] ; Jigna,Patel ^[1] ; Colin,Rose ^[1] ; James,Saenz ^[1] ; Ingrid A,Stock ^[1] ; Gregory,Storer ^[1] ; Maria,VanVolkenburg ^[1] ; Derek,Vrieze ^[1] ; Guoqiang,Wang ^[1] ; Jun,Xiao ^[1] ; Yingxin,Zhang ^[1]

作者单位： Worldwide Medicinal Chemistry, Cardiovascular and Metabolic Research Unit, Pharmacokinetics, Dynamics, and Metabolism, Primary Pharmacology Group, and Pharmaceutical Sciences, Pfizer Global Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States. ^[1]

关键词 Ghrelin PF-5190457 diabetes ghrelin receptor antagonist ghrelin receptor inverse agonist

DOI 10.1021/ml400473x

PMID 24900864

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交